Latest Health News
89bio, Inc. Announces Agreement to be Acquired by Roche
September 18, 2025 01:02 ET | Source: 89bio, Inc. – 89bio stockholders…
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe…
Science Based Targets initiative (SBTi) validates EUROAPIs near-term climate targets
42% reduction in Scope 1 and 2 Greenhouse Gas emissions by 2030…
Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms…
ALK and GenSci partner to expand the AIT market in China
Inside Information GenSci is granted exclusive rights to ALK’s house dust mite…
Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a…
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA)…
AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
PHOENIX and LONDON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc.…
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…
